Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma

[31] Lopez-Martin A(2012)EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 33-1047

[32] Lu HY(2013)Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer Int J Cancer 133 898-8785

[33] Mountzios G(2003)Kit expression in small cell carcinomas of the lung: effects of chemotherapy Mod Pathol 16 1041-1116

[34] Dimopoulos MA(2005)Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung J Clin Oncol 23 8774-227

[35] Soria JC(2012)Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 44 1111-370

[36] Sanoudou D(2010)Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer Clin Lung Cancer 11 223-553

[37] Papadimitriou CA(2012)Improving treatment of HER2-positive cancers: opportunities and challenges Sci Transl Med 4 127rv122-279

[38] Nakachi I(2012)Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 77 365-944

[39] Niho S(1991)Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases Am J Surg Pathol 15 529-1331

[40] Nitta H(1998)Reproducibility of neuroendocrine lung tumor classification Hum Pathol 29 272-undefined

[31] Lopez-Martin A(2012)EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 33-1047

[32] Lu HY(2013)Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer Int J Cancer 133 898-8785

[33] Mountzios G(2003)Kit expression in small cell carcinomas of the lung: effects of chemotherapy Mod Pathol 16 1041-1116

[34] Dimopoulos MA(2005)Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung J Clin Oncol 23 8774-227

[35] Soria JC(2012)Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 44 1111-370

[36] Sanoudou D(2010)Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer Clin Lung Cancer 11 223-553

[37] Papadimitriou CA(2012)Improving treatment of HER2-positive cancers: opportunities and challenges Sci Transl Med 4 127rv122-279

[38] Nakachi I(2012)Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 77 365-944

[39] Niho S(1991)Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases Am J Surg Pathol 15 529-1331

[40] Nitta H(1998)Reproducibility of neuroendocrine lung tumor classification Hum Pathol 29 272-undefined